Clinical Research Directory
Browse clinical research sites, groups, and studies.
Evaluation of the Relevance of Antithrombin Prescriptions at Strasbourg University Hospitals
Sponsor: University Hospital, Strasbourg, France
Summary
Antithrombin (AT) is a physiological inhibitor of the coagulation cascade. In therapeutics, its presence in sufficient quantities is necessary for the pharmacological activity of unfractionated heparin (UFH) and partially low-molecular-weight heparin (LMWH). In intensive care, patients are mostly treated with anticoagulants for either preventive or curative purposes, particularly for those whose care requires renal replacement therapy (RRT), extracorporeal membrane oxygenation (ECMO), or cardiopulmonary bypass (CPB). The use of various types of membranes associated with these procedures can lead to degradation of blood proteins (including AT). An imbalance in hemostasis can then occur, resulting in ineffective anticoagulation. At the Strasbourg University Hospitals (HUS), these medications are directly available in the intensive care units, allowing for immediate administration in an emergency. Pharmaceutical and medical analysis is therefore not performed before administration.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
160
Start Date
2024-12-18
Completion Date
2025-12-31
Last Updated
2025-12-10
Healthy Volunteers
No
Conditions
Locations (1)
Service d'Anesthésie et Réanimation chirurgicale - CHU de Strasbourg - France
Strasbourg, France